Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

NCT02145143 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Carcinoma

Interventions

DRUG: Vemurafenib
DEVICE: serial 124I PET/CT
DRUG: thyrotropin alpha

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]